Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) were flat in after-market trading after the company reported Q3 results.. Quarterly Results. Over the last year we saw more insider selling of Arrowhead Pharmaceuticals shares, than buying. Arrowhead Pharmaceuticals share price volatility. Arrowhead Pharmaceuticals is an inherently innovative biotech. Arrowhead Stock Drops After RNAi Therapeutic Shows Lung Inflammation In Animal Models. The latest closing stock price for Arrowhead Pharmaceuticals as of November 18, 2021 is 70.75.. After all, . The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ARWR will outperform the market and that investors should add to their positions of Arrowhead Pharmaceuticals. Backlinks from other websites are the lifeblood of our site and a primary source of new traffic. Arrowhead Pharmaceuticals Inc is an American biotechnology company. marketingsentinel 10/23/2021. The all-time high Arrowhead Pharmaceuticals stock closing price was 162.34 on June 16, 2000.; The Arrowhead Pharmaceuticals 52-week high stock price is 93.66, which is 32.4% above the current . Learn More. ARWR Arrowhead Pharmaceuticals, Inc — Stock Price and Discussion | Stocktwits. Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) has voluntarily paused the AROENaC1001 Phase 1/2 study evaluating ARO-ENaC for cystic fibrosis. Upright in the red during last session for losing -1.29%, in the last five days ARWR remained trading in the red while hitting it's week-highest on Thursday, 10/21/21 when the stock touched $66.03 price level, adding 2.47% to its value on the day. ARWR earnings call for the period ending March 31, 2020. Amidst increased demand for forensic accounting skills, even for entry-level accountants, this text equips students with the knowledge and skills they need to successfully engage in the field. 10 stocks we like better than Arrowhead Pharmaceuticals When our award-winning analyst team has a stock tip, it can pay to listen. But today's tumble means relatively little for investors with a long-term mindset. Primary metrics and data points about Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) trade information. The . The company employs a staff of tax and financial professionals dedicated to helping business owners and investors proactively implement tax strategy designed to take advantage of the tax law and capture the inherent benefits therein.This ... Arrowhead stock closed the last session at $84.96, an increase of 2.58% or $2.14. This biotech underdog offers more than meets the eye. Arrowhead Pharmaceuticals Inc. () Stock Market info Recommendations: Buy or sell Arrowhead Pharmaceuticals stock? Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The flip side of that is that there are more than a few examples of insiders dumping stock prior to a period of weak performance. Arrowhead Pharmaceuticals, Inc. Common Stock (ARWR) Nasdaq Listed; Nasdaq 100; Data is currently not available. After a stellar 2019, the biotech stock has lost 47% so far in 2020. Type a symbol or company name. Analysts expect earnings per share of $0.048. Arrowhead Pharmaceuticals insiders own 3.2% of the company, currently worth about US$295m based on the recent share price. Please check your download folder. Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The stock price of Arrowhead, a biopharmaceutical company that develops RNA interference therapies, has seen a large 30% fall over the last five trading days. /*-->*/. The Fool has written over 100 articles on Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' stock was trading at $28.56 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Officers with the Supreme Court police discover a shocking crime--an anonymous person has smuggled a dead baby into the Supreme Court building. [CDATA[>*/ ARWR earnings call for the period ending June 30, 2021. Arrowhead Pharmaceuticals, Inc. Common Stock (ARWR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Arrowhead Pharmaceuticals stock price target raised to $46 from $32 at B. Riley FBR. By clicking on the graph below, you can see the precise details of each insider transaction! Its portfolio includes drugs targeting hepatitis B, Alpha . Arrowhead Pharma in License Agreement With GSK for ARO-HSD. Outsmart the market with Smart Portfolio analytical tools powered by TipRanks. Alternatively, email editorial-team (at) simplywallst.com. 0. Its medical solutions are aimed at the genes that trigger the diseases. Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Wall Street Stock Market & Finance report, prediction for the future: You'll find the Arrowhead Pharmaceuticals share forecasts, stock quote and buy / sell signals below.According to present data Arrowhead Pharmaceuticals's ARWR shares and potentially its market environment have . Find the latest Arrowhead Pharmaceuticals, Inc. (ARWR) stock quote, history, news and other vital information to help you with your stock trading and investing. Dr. San Martin owns 130,500 shares of Arrowhead Pharmaceuticals stock worth more than $9,251,145 as of November 24th. This book is the first to provide balanced examination of both pediatric liver disease and liver transplantation – two topics that are inherently related, given that most chronic liver disorders eventually require organ replacement. Found inside – Page 48... + 35.38 36.02 26.61 ARWM U N / A 1.81 1.40 ARWR D3.94 8.00 2.02 D1.05 1.60 0.70 ARTG AMSI E 2.65 3.25 1.35 ARTNB с 21.00 29.75 21.00 ARTNA с 26.03 29.76 22.79 ATSN C + 9.25 11.30 7.30 ARTC с 28.42 33.11 19.76 AJG B 28.75 33.96 27.06 ... Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. [CDATA[/* >